Swedbank AB Acquires 51,000 Shares of Moderna, Inc. (NASDAQ:MRNA)

Swedbank AB increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 149.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 85,099 shares of the company’s stock after purchasing an additional 51,000 shares during the quarter. Swedbank AB’s holdings in Moderna were worth $5,687,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. International Assets Investment Management LLC boosted its position in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after purchasing an additional 316,552 shares during the period. State of Michigan Retirement System increased its stake in Moderna by 201.9% in the 2nd quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock worth $32,567,000 after buying an additional 183,407 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after acquiring an additional 167,596 shares during the period. Citigroup Inc. lifted its position in shares of Moderna by 30.5% in the third quarter. Citigroup Inc. now owns 591,910 shares of the company’s stock valued at $39,557,000 after acquiring an additional 138,378 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of Moderna by 75.4% in the third quarter. Van ECK Associates Corp now owns 266,929 shares of the company’s stock worth $17,839,000 after acquiring an additional 114,769 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 1,147 shares of company stock valued at $76,245 in the last 90 days. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. TD Cowen lowered their price target on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Berenberg Bank started coverage on shares of Moderna in a report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and reduced their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $83.26.

Moderna Stock Up 3.2 %

Shares of NASDAQ:MRNA opened at $43.39 on Thursday. The firm has a market capitalization of $16.70 billion, a PE ratio of -7.46 and a beta of 1.69. The business has a 50 day simple moving average of $53.32 and a two-hundred day simple moving average of $92.28. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the business earned ($1.39) EPS. Moderna’s revenue was up 3.8% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -9.44 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.